Exploring the Prognostic Value and Immune Infiltration Patterns of GPRC5A Across Multiple Cancer Types

Song Hu ¹, Yan Chen ¹, Beibei Sun ²

⁰Department of Clinical Laboratory Medicine, Shanghai Tenth People's Hospital of Tongji University School of Medicine, Shanghai, China.

Journal of Cancer +

|

July 15, 2024

View abstract on PubMed

Summary

This study reveals that GPRC5A expression varies across cancers and links to patient survival and the tumor immune microenvironment. GPRC5A shows promise as a prognostic biomarker and therapeutic target in oncology.

Area Of Science

Oncology
Molecular Biology
Cancer Genomics

Background

The role of G protein-coupled receptor class C group 5 member A (GPRC5A) in various cancers remains incompletely understood.
Investigating GPRC5A expression patterns and clinical correlations is crucial for identifying novel biomarkers and therapeutic targets.

Purpose Of The Study

To comprehensively analyze GPRC5A expression across a wide range of cancers.
To evaluate the association between GPRC5A expression and clinical outcomes, including survival and clinicopathological features.
To explore the relationship between GPRC5A and the tumor immune microenvironment and its functional implications.

Main Methods

Utilized The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), and Human Protein Atlas (HPA) databases for expression analysis.
Performed Kaplan-Meier survival analysis, correlation analyses with clinical parameters, and nomogram modeling.
Analyzed tumor immune microenvironment correlations using GEPIA2 and conducted functional enrichment analyses.

Main Results

GPRC5A showed differential expression in pan-cancer, with high expression in 11 cancer types.
Aberrant GPRC5A expression correlated significantly with overall survival, disease-specific survival, and progression-free interval in specific cancers.
GPRC5A expression was linked to clinicopathological features, the tumor immune microenvironment, and biological functions, with nomogram models showing clinical utility for predicting survival.

Conclusions

GPRC5A is differentially expressed in pan-cancer and serves as a potential prognostic biomarker and therapeutic target.
GPRC5A's association with the tumor immune microenvironment suggests a role in anti-tumor immunity.
These findings offer valuable insights into GPRC5A's biological roles and clinical significance in cancer.